Felix Biotechnology was founded in 2019 to accelerate the deployment of novel biotherapeutics treating microbial infections, a growing threat in human health and beyond. It combines cutting-edge synthetic biology technologies from Yale and Berkeley into a pipeline that enables it to target, engineer, and deploy biotherapeutics against a wide range of bacterial infections, including those resistant to existing antibiotics. Felix’s therapies overcome the challenges faced by traditional antibiotics by uniquely target the key mechanisms underlying bacterial antibiotic resistance, driving bacterial evolution to states of antibiotic susceptibility or reduced virulence, and ensuring a treatment option is always available.
Felix’s lead clinical asset targets antibiotic-resistant Pseudomonas aeruginosa infections in cystic fibrosis patients and has already been deployed in 10 patients through non-dilutively funded compassionate use. In all cases, no adverse safety events were noted, bacterial load was reduced and in some cases eliminated, and remaining bacteria were susceptible to antibiotics. Building on this success, Felix is seeking tranched Series A funds to develop this asset commercially. Simultaneously, it is continuing development of an exciting pipeline targeting antibiotic-resistant bacteria such as Staphylococcus aureus, Escherichia coli, and other undisclosed pathogens to once again make microbial infections a threat of the past.